1
2
3
4
5
6
7
8
9
10
11
12
13 | Licensing Program Analyst (LPA) Kimberly Lyman conducted an unannounced visit for the purpose of initiating an investigation on the above allegations. LPA was greeted and granted entry into the facility and explained the reason for the visit.
During the course of the investigation, LPA toured the facility, interviewed staff and witnesses as well as reviewed and obtained pertinent documentation such as medication records and physician report. Regarding the allegations that medication was not adminstered to resident according to their physician's orders and resident developed skin rash(es) while in care, the investigation revealed the following: R1 had a medication order for Miralax, generic Polyethylene Glycol, as a PRN order. Order stated to take "As needed." Facility states resident was not in need of it and was taking Senna PRN and Docusate Sodium daily. Medication records indicate resident was receiving the Docusate Sodium, Senna, and two instances of the Miralax. Resident had a skin rash suspected by physician to be Scabies. Two witnesses and three staff confirm R1 was seen by a physician immediately for the skin condition. Facility stated there was no Scabies outbreak at the facility. Per Administrator, a subsequent appointment with CONT ON LIC 9099C DATED 05/25/2022 |